加载中
NASDAQHealthcareBiotechnology
最新数据
US$12.50
+US$0.40 · +3.31%
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
前收盘价
US$12.50
+US$0.40 · +3.31%
盘中时间采用ET。市场数据可能有所延迟。
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
日内区间
当前US$12.50
52周区间
当前US$12.50
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
55
合理估值
情绪
57
多空交织
风险
53
风险偏高
动量
49
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
日内区间
当前US$12.50
52周区间
当前US$12.50
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6532.4万 USD | 6763.5万 USD | 7920.4万 USD | 8616万 USD | 9707.4万 USD |
| 销货成本 | 458.6万 USD | — | — | — | — |
| 毛利 | 6073.8万 USD | 6763.5万 USD | 7920.4万 USD | 8616万 USD | 9707.4万 USD |
| 研究与开发 | 1.07亿 USD | 1.31亿 USD | 1.64亿 USD | 1.65亿 USD | 1.74亿 USD |
| 销售、一般及管理费用 | 4393.3万 USD | 5785万 USD | 5288.7万 USD | 4548.2万 USD | 3253.6万 USD |
| 营业费用 | 1.46亿 USD | 1.89亿 USD | 2.16亿 USD | 2.1亿 USD | 2.07亿 USD |
| 利息收入 | 948.1万 USD | 1477万 USD | 1136万 USD | 157.3万 USD | 202.1万 USD |
| 利息支出 | 768.1万 USD | 1094万 USD | 514.8万 USD | — | — |
| 折旧和摊销 | 508.9万 USD | 233.6万 USD | 237.1万 USD | 297.3万 USD | 333.4万 USD |
| 营业利润 | −8534.9万 USD | −1.22亿 USD | −1.37亿 USD | −1.24亿 USD | −1.1亿 USD |
| 净利润 | −8188.9万 USD | −1.16亿 USD | −1.34亿 USD | −1.22亿 USD | −7899.6万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$20.00
上涨空间 60.00%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1169.2万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM909.91万0.01%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF417.95万0.00%954亿 USD0.05%US$235+0.80%
iShares Biotechnology ETFIBB258.54万0.02%108.2亿 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO217.51万0.01%180亿 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA164.42万0.01%218.24亿 USD0.03%US$32.79+0.40%
Dimensional - US Small Cap ETFDFAS158.33万0.00%338.69亿 USD0.31%US$78.35+0.32%
iShares Russell 2000 Growth ETFIWO156.16万0.01%139.17亿 USD0.24%US$356.78+0.94%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHADimensional - US Small Cap ETFDFASiShares Russell 2000 Growth ETFIWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
